CAR T-cell therapy successfully treats myeloma in Hong Kong
A CAR T-cell therapy manufactured in mainland China has been successfully deployed for the first time in Hong Kong to treat a man with myeloma,…
Marisa Wexler, MS, senior science writer — 
Articles by Marisa Wexler
Phase 3 CLL/SLL trial of ICP-248 plus orelabrutinib doses first patient
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
Cabometyx wins FDA approval for treating certain pancreatic cancers
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
Glioblastoma trial of VXM01 plus Bavencio shows promising safety
Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…
Nemvaleukin plus Keytruda fails in Phase 3 trial in ovarian cancer
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
Personalized cancer vaccine shows potential in myeloma, solid tumors
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
OSE2101 vaccine shows ‘promising benefit’ in pancreatic cancer trial
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
EU committee recommends Jaypirca for certain leukemia patients
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic leukemia (CLL), a type of…
Immunotherapy shows promise as treatment for pancreatic cancer
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
High-risk genetic changes with myeloma tied to poorer outcomes
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
